The growth rate of the DPP-4i market increased slightly

Sales of DPP-4 inhibitors rose 1.3% year-on-year to 611.3 billion won last year

Zemiglo, Sugaron, and Tenelia's sales performance have expanded

The domestic DPP-4i diabetes treatment market, which is formed at 600 billion won a year, slowed down last year.

 

It recorded the lowest growth rate in the last seven years.

 

In the DPP-4 inhibitor market, where growth has slowed, the position of domestic companies has also expanded significantly.

 

Rx sales for foreign company products fell.

 

◆DPP-4 inhibitor, growth rate of 1% in 7 years According to UBIST, a pharmaceutical market research firm, on the 19th, the total market for DPP-4 inhibitors last year was 611.3 billion won, up 1.3% from a year earlier.

 

The growth rate of the DPP-4 inhibitor market is the lowest since 2014.

 

In the past seven years, the market for DPP-4 inhibitors has grown rapidly.

 

It increased 21.5% from 299.5 billion won in 2014 to 363.9 billion won in 2015.

 

Since then, it has surpassed 600 billion won for the first time, recording 437.6 billion won in 2016, 468.6 billion won in 2017, 502.3 billion won (7.1%) in 2018, 569.1 billion won (13.2%) in 2019, and 602.9 billion won (5.9%) in 2020.

 

Since MSD's Januvia was released in 2007, it has become a trend by replacing existing diabetes drugs.

 

Since then, nine active ingredients have been released in the DPP-4 inhibitor market and are fiercely competing.

 

◆LG Chem, Dong-A ST, and Handok's expansion of influence in the DPP-4i market It was confirmed that domestic companies made strides in the DPP-4i market last year.

 

The prescription amount of all three domestic pharmaceutical companies, LG Chem, Dong-A ST, and Handok, has increased.

 

LG Chem's three types of Zemiglo prescriptions, Zemiglo, Zemimet, and Zemiro, totaled 130.3 billion won, up 8.8% from the previous year.

 

The market share also expanded 2.1%p from 19.2% in 2020 to 21.3% last year.

 

Despite the slowing growth of Zemiglo , the combination drug has expanded its influence.

 

Zemiglo's prescription amount last year was 38.9 billion won, up 2.6% from the previous year.

 

Sales of Zemimet reached 90.8 billion won over the same period, up 11.6% from the previous year.

 

Dong-A ST's self-developed new drug Suganon series also saw its prescription amount rise.

 

Last year, the total amount of prescriptions, including Suganon and Sugamet, surpassed 30 billion won for the first time with 32.6 billion won.

 

The market share was 5.3%, an increase of 1.3%p from the previous year.

 

Suganon's outpatient prescriptions last year amounted to 13 billion won, up 23.51% from a year earlier.

 

During the same period, Sugamet also increased 39.72% to 19.6 billion won.

 

Handok's Tenelia series recorded 46.2 billion won in prescriptions last year.

 

Tenelia's prescription amount was 21.4 billion won, up 83% from the previous year.

 

During the same period, Tenelia M (Tenerigliptin + Metformin) increased by 9% to 24.8 billion won.

 

◆ Multinational corporation DPP-4 inhibitor, slowing prescription performance The prescription performance of items from multinational companies has fallen.

 

Last year, the total amount of prescriptions for the MSD Januvia products was 171 billion won, down 2.9% from a year earlier.

 

Among the Januvia products, the decrease in prescriptions for Januvia was the largest at 5.8%.

 

Sales of Janumet fell 3.8% from the previous year to 76.2 billion won, while Janumet XR's sales rose 1.8% to 50.4 billion won.

 

Sales of the Trajenta prodcuts also slowed down.

 

It decreased by 1.5% from 61.6 billion won to 60.7 billion won.

 

Trajenta Duo's sales recorded 65.5 billion won, down 2.6%.

 

Sales of Novartis' Galvus products decreased by 0.8% from 47 billion won to 46.6 billion won, and Sales of Takeda's Nesina fell 3.7% from 32.1 billion won to 30.9 billion won.

 

In 2020, Takeda sold its rights to Celltrion in the Asia-Pacific region of 18 Rx drugs and OTC drugs.

 

It was found that Nesina's transfer process has not yet been completed.

 

Sales of AstraZeneca's Onglyza and Kombiglyze also fell 1.2% from 27.6 billion won in 2020 to 27.3 billion won last year.